<turbo-stream action="append" target="news"><template>  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Regeneron-Pharmaceuticals-US75886F1075">Regeneron Pharmaceuticals</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Business Wire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">4 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.businesswire.com/news/home/20260518371841/en/Parabilis-Medicines-Announces-Strategic-Collaboration-with-Regeneron-Pharmaceuticals-to-Advance-Novel-Antibody-Helicon%E2%84%A2-Conjugates-Across-Multiple-Therapeutic-Areas/">Parabilis Medicines Announces Strategic Collaboration with Regeneron Pharmaceuticals to Advance Novel Antibody-Helicon™ Conjugates Across Multiple Therapeutic Areas</a>
    </div>

      <div class="me-0 me-md-5">
        CAMBRIDGE, Mass.--(BUSINESS WIRE)--Parabilis Medicines today announced a strategic research collaboration with Regeneron Pharmaceuticals, Inc. to discover and develop multiple therapeutic candidates based on Parabilis&#39;s Helicon™ peptide platform, with a particular focus on Antibody-Helicon™ Conjugates (AHCs), a novel class of therapeutics designed to target challenging and historically “undrugg...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-danger bg-red-100">
          Negative
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Regeneron-Pharmaceuticals-US75886F1075">Regeneron Pharmaceuticals</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Reuters</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">4 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.reuters.com/business/healthcare-pharmaceuticals/regeneron-drops-after-skin-cancer-treatment-misses-late-stage-trial-goal-2026-05-18/">Regeneron drops after skin cancer treatment misses late-stage trial goal</a>
    </div>

      <div class="me-0 me-md-5">
        Shares of Regeneron fell 11.8% premarket on Monday after the company&#39;s ​experimental treatment missed the main goal in ‌a late-stage trial in patients with advanced melanoma, a type of skin cancer.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Regeneron-Pharmaceuticals-US75886F1075">Regeneron Pharmaceuticals</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">4 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/05/16/3296192/0/en/Regeneron-Provides-Update-on-Phase-3-Trial-of-Fianlimab-LAG-3-Inhibitor-Combination-in-First-Line-Unresectable-or-Metastatic-Melanoma.html">Regeneron Provides Update on Phase 3 Trial of Fianlimab (LAG-3 Inhibitor) Combination in First-Line Unresectable or Metastatic Melanoma</a>
    </div>

      <div class="me-0 me-md-5">
        The trial did not reach statistical significance for the primary endpoint of improvement in progression-free survival (PFS) A numeric improvement of 5.1 months in median PFS was observed for the high-dose fianlimab combination compared to pembrolizumab monotherapy Phase 3 head-to-head trial of the high-dose fianlimab combination versus Opdualag ® (nivolumab and relatlimab-rmbw) is ongoing TARRY...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Regeneron-Pharmaceuticals-US75886F1075">Regeneron Pharmaceuticals</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">4 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/05/15/3296179/0/en/UPDATE-Next-Generation-of-Scientific-Leaders-Awarded-More-Than-7-Million-at-the-2026-Regeneron-International-Science-and-Engineering-Fair.html">UPDATE – Next Generation of Scientific Leaders Awarded More Than $7 Million at the 2026 Regeneron International Science and Engineering Fair</a>
    </div>

      <div class="me-0 me-md-5">
        TARRYTOWN, N.Y. and WASHINGTON, May 15, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc., and Society for Science (the Society) announced that Hikaru Kuribayashi , 17, of Sapporo, Japan won the $100,000 George D.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Regeneron-Pharmaceuticals-US75886F1075">Regeneron Pharmaceuticals</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">4 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/05/15/3296082/0/en/Next-Generation-of-Scientific-Leaders-Awarded-More-Than-7-Million-at-the-2026-Regeneron-International-Science-and-Engineering-Fair.html">Next Generation of Scientific Leaders Awarded More Than $7 Million at the 2026 Regeneron International Science and Engineering Fair</a>
    </div>

      <div class="me-0 me-md-5">
        Hikaru Kuribayashi, 17, receives $100,000 Top Award for his creation of a simulation program to understand complex folding at the world&#39;s largest pre-college STEM competition. TARRYTOWN, N.Y.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Regeneron-Pharmaceuticals-US75886F1075">Regeneron Pharmaceuticals</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">5 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/05/08/3290991/0/en/Regeneron-Named-to-Dow-Jones-Best-in-Class-World-Index-for-Global-Responsibility-Leadership-for-Seven-Consecutive-Years.html">Regeneron Named to Dow Jones Best-in-Class World Index for Global Responsibility Leadership for Seven Consecutive Years</a>
    </div>

      <div class="me-0 me-md-5">
        Regeneron also earns spot on Dow Jones Best-in-Class North America Index for six consecutive years Recognition complements the company&#39;s recent announcement that it will provide its new gene therapy for a form of genetic hearing loss for free in the United States, reinforcing its commitment to patient access New science-led 2030 responsibility goals reflect Regeneron&#39;s commitment to corporate r...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Regeneron-Pharmaceuticals-US75886F1075">Regeneron Pharmaceuticals</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">5 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/05/05/3287485/0/en/Dupixent-dupilumab-Demonstrates-Improved-Esophageal-Function-in-Eosinophilic-Esophagitis-EoE-Phase-4-Trial.html">Dupixent® (dupilumab) Demonstrates Improved Esophageal Function in Eosinophilic Esophagitis (EoE) Phase 4 Trial</a>
    </div>

      <div class="me-0 me-md-5">
        Dupixent showed significant and clinically meaningful improvements in both esophageal distensibility as well as disease-related structural changes and inflammation in the esophagus in adult patients with EoE at week 24 compared to placebo, in results presented at DDW
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-danger bg-red-100">
          Negative
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Regeneron-Pharmaceuticals-US75886F1075">Regeneron Pharmaceuticals</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Proactive Investors</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">5 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.proactiveinvestors.com/companies/news/1091431?SNAPI">Regeneron shares slide despite Q1 beat</a>
    </div>

      <div class="me-0 me-md-5">
        Regeneron Pharmaceuticals Inc (NASDAQ:REGN) shares fell more than 5.5% on Wednesday morning even as the drugmaker reported better-than-expected first-quarter results and announced a new share repurchase program worth up to $3 billion. Revenue rose 19% year-over-year to $3.605 billion for the quarter ended March 31, while adjusted earnings came in at $9.47 per share, both topping Wall Street for...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

</template></turbo-stream><turbo-stream action="replace" target="link"><template><div id="link">
    <a class="btn btn-outline-primary btn--small" data-turbo-stream="" href="/en/news/Regeneron-Pharmaceuticals-US75886F1075/load_more?page=5">
      Show more News
      <i class="fa fa-arrow-down fa-fw"></i>
</a></div>
</template></turbo-stream>